QN
QNCX.US Quince Therapeutics, Inc.
- Market cap
- USD 32.3M
- P/E
- -
- P/B
- 2.21x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is QNCX.US undervalued?
Graham numberThe Graham number of Quince Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Quince Therapeutics, Inc. fundamental analysis
No fundamental analysis for Quince Therapeutics, Inc. yet.
Quince Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device …
Full company profileQuince Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Quince Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -45.0K | -51.0K | -188K | -332K | -344K | -175K | -322K | -186K | -142K | - |
| Operating Income | -10.4M | -12.1M | -39.2M | -78.9M | -90.3M | -52.0M | -34.6M | -57.3M | -50.4M | -139M |
| EBITDA | -10.3M | -12.1M | -39.0M | -78.6M | -89.6M | -51.0M | -26.8M | -36.0M | -80.6M | -77.2M |
| Net Income | -12.2M | -12.5M | -37.0M | -76.8M | -89.9M | -51.7M | -31.4M | -56.8M | -84.0M | -89.8M |
| EPS | -114 | -116 | -389 | -527 | -605 | -308 | -169 | -263 | -335 | -7.48 |
| Balance Sheet | ||||||||||
| Total Assets | 7.72M | 72.9M | 124M | 189M | 133M | 104M | 180M | 114M | 93.5M | 106M |
| Total Liabilities | 28.0M | 1.46M | 8.89M | 17.2M | 14.6M | 3.32M | 95.1M | 84.3M | 129M | 28.4M |
| Shareholders' Equity | -20.3M | 71.4M | 115M | 172M | 119M | 101M | 85.1M | 30.1M | -35.7M | -65.7M |
| Cash & Short-term Investments | 7.34M | 71.7M | 99.9M | 134M | 107M | 90.2M | 75.1M | 40.8M | 17.8M | 105M |
| Total Debt | 7.17M | - | - | 446K | 1.16M | 453K | 13.8M | 14.8M | 18.5M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -9.83M | -11.7M | -33.3M | -50.8M | -62.9M | -44.0M | -18.3M | -31.9M | -41.4M | -48.5M |
| Capital Expenditure | 77.0K | 212K | 55.0K | 52.0K | 180K | 133K | 160K | 257K | 352K | 100K |
| Free Cash Flow | -9.90M | -11.9M | -33.3M | -50.9M | -63.1M | -44.2M | -18.5M | -32.2M | -41.8M | -48.6M |
| Ratios | ||||||||||
| ROE | - | -17.5% | -32.0% | -44.6% | -75.8% | -51.4% | -36.9% | -188.5% | - | - |
| ROA | -158.5% | -17.1% | -29.7% | -40.6% | -67.5% | -49.7% | -17.4% | -49.6% | -89.8% | -84.3% |
| Debt to Equity | - | - | - | 0.00x | 0.01x | 0.00x | 0.16x | 0.49x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Quince Therapeutics, Inc. dividends
Quince Therapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Jun 30, 2026.
Who owns Quince Therapeutics, Inc.
- Insiders 2.90%
- Institutions 34.50%
- Public & others 62.60%
- Shares outstanding 1.02M
- Free float 680K
Top funds holding QNCX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 5.34K | 0.05% | -0.37% | Sep 2026 |
| Fidelity Series Total Market Index | 1.25K | 0.01% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.15K | 0.01% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 580.00 | 0.01% | 0.00% | Aug 2026 |
| Guggenheim Active Allocation Fund | 2.00 | 0.00% | +100.00% | Aug 2026 |
Top institutions holding QNCX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Ikarian Capital, LLC | 72.3K | 0.36% | 0.00% | Jun 2026 |
| Millennium Management LLC | 70.8K | 0.35% | +465.37% | Jun 2026 |
| Balyasny Asset Management LLC | 70.0K | 0.34% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 40.4K | 0.20% | 0.00% | Jun 2026 |
| Shay Capital LLC | 17.5K | 0.09% | +97.04% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 13.9K | 0.07% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 12.6K | 0.06% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.0K | 0.06% | +422.06% | Jun 2026 |
| Cormorant Asset Management, LLC | 5.50K | 0.03% | 0.00% | Jun 2026 |
| UBS Group AG | 4.73K | 0.02% | +157,566.67% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.08K | 0.02% | +102,000.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 3.61K | 0.02% | +211.02% | Jun 2026 |
| BlackRock Inc | 1.70K | 0.01% | -28.06% | Jun 2026 |
| Tower Research Capital LLC | 567.00 | 0.00% | +1,188.64% | Jun 2026 |
| Operose Advisors LLC | 159.00 | 0.00% | 0.00% | Jun 2026 |
| Fortitude Family Office LLC | 40.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 27.00 | 0.00% | 0.00% | Jun 2026 |
| Integrated Wealth Concepts LLC | 12.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 10.00 | 0.00% | 0.00% | Jun 2026 |
| Hanson Mcclain Inc | 8.00 | 0.00% | 0.00% | Jun 2026 |
Quince Therapeutics, Inc. company profile
- Company name
- Quince Therapeutics, Inc.
- Ticker
- QNCX.US
- Exchange
- USA Stocks
- Listed since
- May 9, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 38
- Fiscal year end
- December
- Address
- 611 Gateway Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 415 910 5717
- Website
- quincetx.com
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Quince Therapeutics, Inc. management
4- Dr. Brigette Roberts M.D.CEO, Principal Executive Officer & Director · born 1975
- Mr. John C. Militello C.P.A.CFO, Principal Financial Officer & Principal Accounting Officer · born 1973
- Dr. Keith R. Fandrick Ph.D.Chief Operating Officer · born 1979
- Dr. Guenter R. Janhofer M.D., Ph.D.Chief Scientific Officer